Boehringer Ingelheim study shows cost-effectiveness benefits of Pradaxa

Boehringer Ingelheim announced new data from a real-world analysis showing how its novel oral anticoagulant Pradaxa can help reduce healthcare resource utilisation levels.

Data was collated from among nearly 4,000 recently-diagnosed non-valvular atrial fibrillation patients newly treated with Pradaxa or warfarin, showing that Pradaxa recipients experienced fewer all-cause annual hospitalisations, emergency room visits and physician office visits.

This is the first study to compare the respective impact on the use of healthcare resources between Pradaxa and warfarin, and will help physicians to better understand the experiences patients are having in real-world settings.

Results from Boehringer Ingelheim's clinical trial programme to date have shown that Pradaxa offers superior efficacy and a favourable risk-benefit profile compared to warfarin.

Dr Sabine Luik, senior vice-president for medicine and regulatory affairs at Boehringer Ingelheim Pharmaceuticals, said: "We strongly believe that real-world data are critical in order to better understand the potential of our therapies in helping improve patient outcomes and facilitating efficient use of healthcare resources."

The Boehringer Ingelheim research programme for Pradaxa has involved more than 120,000 patients worldwide to date.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.